Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC | MicrobiomeTrials← Back to trialsNCT06552234
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-10-01Est. Completion: 2031-09
Enrollment target: 30 participants Locations- CH Aix-en-Provence, Aix-en-Provence, Bouches Du Rhône, France
- AP-HM, Marseille, Bouches Du Rhône, France
- HIA Sainte Anne, Toulon, Var, France
- CHU Angers, Angers, France
- CHU Bordeaux, Bordeaux, France
- CHU Brest, Brest, France
- Centre François Baclesse, Caen, France
- CH Chambéry, Chambéry, France
- Hôpitaux civils de Colmar, Colmar, France
- CHI Créteil, Créteil, France
- CHD Vendée, La Roche-sur-Yon, France
- CHRU Lille, Lille, France
- CHU Limoges, Limoges, France
- Hospices Civils de Lyon, Lyon, France
- CH Cornouaille, Quimper, France
- CHU Rennes, Rennes, France
- CHU Rouen, Rouen, France
- Hôpital Foch, Suresnes, France
- CHU Toulouse, Toulouse, France
- Hôpitaux Nord-Ouest, Villefranche-sur-Saône, France
Other microbiome trials you might be interested in
Advanced/Metastatic Non-Small Cell Lung Cancer
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metas…
Goodyear, United StatesEst. completion Jun 24, 2030
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatm…
Anchorage, United StatesEst. completion Dec 31, 2026